Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Advanced Bladder Cancer: Adopting Newer Therapies into Clinical Practice

February 3rd 2022

Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve

Key Takeaways on the Management of Metastatic Urothelial Carcinoma

January 25th 2022

Clinical pearls of advice regarding the optimal management of metastatic urothelial carcinoma in today’s treatment landscape.

Metastatic Urothelial Carcinoma: Second-Line Therapy and Beyond

January 25th 2022

Expert perspectives on novel treatment approaches being investigated in the second-line setting of metastatic urothelial carcinoma and beyond.

Practical Advice on Use of Maintenance Therapy in mUC

January 18th 2022

Practical advice on maintenance therapy in metastatic urothelial carcinoma, covering patient education, duration of therapy, and clinical guidelines.

Metastatic Urothelial Carcinoma: Interpreting JAVELIN Bladder 100

January 18th 2022

A review of the JAVELIN Bladder 100 trial, which evaluated avelumab maintenance therapy following frontline chemotherapy in metastatic urothelial carcinoma.

Impact of Maintenance Therapy on Metastatic Urothelial Carcinoma

January 11th 2022

The overall impact that maintenance therapy has had on patient outcomes in advanced or metastatic urothelial carcinoma.

Treatment Options for Newly Diagnosed Metastatic Urothelial Carcinoma

January 11th 2022

Expert perspectives on optimal treatment approaches in patients with newly diagnosed metastatic urothelial carcinoma.

The Landscape of Advanced Urothelial Carcinoma

December 23rd 2021

A brief overview of the advanced urothelial carcinoma landscape encompassing disease course and standard of care treatment strategies.

Dr. Bupathi on the Evolving Treatment Landscape of Bladder Cancer

December 3rd 2021

Manojkumar Bupathi, MD, MS, discusses the evolving treatment landscape of bladder cancer.

Dr. Grivas on Enfortumab Vedotin in Second- and Third-Line Urothelial Carcinoma

December 3rd 2021

Petros Grivas, MD, PhD, discusses the utility of enfortumab vedotin-ejfv in the second- and third-line setting for patients with urothelial carcinoma.

CG0070 Plus Pembrolizumab Shows Early Tolerability and Activity in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

November 29th 2021

The combination of CG0070 and pembrolizumab was well tolerated and demonstrated early signals of activity in patients with Bacille Calmette-Guérin-unresponsive non–muscle invasive bladder cancer.

Dr. Vaishampayan on the Future Directions for Second-Line Treatment in Urothelial Cancer

November 23rd 2021

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Dr. Palmbos on Remaining Questions in Metastatic Urothelial Carcinoma

November 22nd 2021

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

November 22nd 2021

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Dr. Yu on the Utility of Enfortumab Vedotin in Metastatic Urothelial Cancer

November 12th 2021

Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer.

Dr. Grivas on Attempts to Improve Upon Chemotherapy in Urothelial Cancer

November 12th 2021

Petros Grivas, MD, PhD, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

N-803 Plus Intravesical BCG Produces 57% DFS in BCG-Unresponsive Papillary Bladder Cancer

October 20th 2021

Intravesical Bacillus Calmette–Guérin in combination with N-803 resulted in a 12-month disease-free survival rate of 57% in patients with BCG-unresponsive high-grade papillary non–muscle invasive bladder cancer, meeting the primary end point for cohort B of the phase 2/3 QUILT 3.032 trial.

UGN-102 May Provide Alternative to Repetitive Surgery in Low-Grade Intermediate-Risk NMIBC

October 19th 2021

Non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 produced significant, durable responses in those with low-grade intermediate-risk non–muscle invasive bladder cancer.

Expanding Armamentarium Underscores the Importance of Close Monitoring in Urothelial Cancer

October 12th 2021

Evan Y. Yu, MD, provided insight into treatment sequencing for patients with metastatic urothelial carcinoma, considerations for treatment decisions, and emerging therapies in the paradigm.

Dr. Chatzkel on the Emergence of Novel Therapies in Metastatic Urothelial Cancer

October 6th 2021

Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.